{
    "root": "0e66ff4c-8aeb-4875-b6d8-1184b4ac27d2",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Tacrolimus",
    "value": "20250520",
    "ingredients": [
        {
            "name": "TACROLIMUS",
            "code": "WM0HAQ4WNM",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00864"
        },
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "D&C RED NO. 28",
            "code": "767IP0Y5NH"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "FD&C RED NO. 3",
            "code": "PN2ZH5LOQY"
        },
        {
            "name": "D&C RED NO. 33",
            "code": "9DBA0SBB0L"
        }
    ],
    "indications": {
        "text": "tacrolimus capsules calcineurin-inhibitor immunosuppressant indicated prophylaxis organ rejection adult pediatric patients receiving allogeneic liver , kidney , heart transplants , combination immunosuppressants . ( 1.1 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 administer capsules consistently without food . ( 2.1 ) \u2022 therapeutic monitoring recommended . ( 2.1 , 2.6 ) \u2022 avoid eating grapefruit drinking grapefruit juice . ( 2.1 ) \u2022 adjustments african-american patients ( 2.2 ) , hepatic renal impaired . ( 2.4 , 2.5 ) \u2022 complete dosing information , full prescribing information . mmf = mycophenolate mofetil adult patient population initial oral whole blood trough concentration range kidney transplant azathioprine 0.2 mg/kg/day capsules , divided two doses , every 12 hours month 1-3 : 7-20 ng/ml month 4-12 : 5-15 ng/ml mmf/il-2 receptor antagonist 0.1 mg/kg/day capsules , divided two doses , every 12 hours month 1-12 : 4-11 ng/ml liver transplant corticosteroids 0.1-0.15 mg/kg/day capsules , divided two doses , every 12 hours month 1-12 : 5-20 ng/ml heart transplant azathioprine mmf 0.075 mg/kg/day capsules , divided two doses , every 12 hours month 1-3 : 10-20 ng/ml month \u2265 4 : 5-15 ng/ml pediatric patient population initial oral whole blood trough concentration range kidney transplant 0.3 mg/kg/day capsules divided two doses , every 12 hours . month 1-12 : 5-20 ng/ml liver transplant 0.15-0.2 mg/kg/day capsules divided two doses , every 12 hours month 1-12 : 5-20 ng/ml heart transplant 0.3 mg/kg/day 2 capsules divided two doses , every 12 hours month 1-12 : 5-20 ng/ml 2. dose 0.1 mg/kg/day antibody induction treatment administered .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "tacrolimus capsules contraindicated patients hypersensitivity tacrolimus . tacrolimus injection contraindicated patients hypersensitivity hco-60 ( polyoxyl 60 hydrogenated castor oil ) . hypersensitivity symptoms reported include dyspnea , rash , pruritus , acute respiratory distress syndrome [ ( 6 ) ] .",
    "indications_original": "Tacrolimus capsules are a calcineurin-inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, or heart transplants, in combination with other immunosuppressants. ( 1.1 )",
    "contraindications_original": "\u2022 Administer capsules consistently with or without food. ( 2.1 ) \u2022 Therapeutic drug monitoring is recommended. ( 2.1 , 2.6 ) \u2022 Avoid eating grapefruit or drinking grapefruit juice. ( 2.1 ) \u2022 See dosage adjustments for African-American patients ( 2.2 ), hepatic and renal impaired. ( 2.4 , 2.5 ) \u2022 For complete dosing information, see Full Prescribing Information. MMF = Mycophenolate mofetil ADULT Patient Population Initial Oral Dosage Whole Blood Trough Concentration Range Kidney Transplant With azathioprine 0.2 mg/kg/day capsules, divided in two doses, every 12 hours Month 1-3: 7-20 ng/mL Month 4-12: 5-15 ng/mL With MMF/IL-2 receptor antagonist 0.1 mg/kg/day capsules, divided in two doses, every 12 hours Month 1-12: 4-11 ng/mL Liver Transplant With corticosteroids only 0.1-0.15 mg/kg/day capsules, divided in two doses, every 12 hours Month 1-12: 5-20 ng/mL Heart Transplant With azathioprine or MMF 0.075 mg/kg/day capsules, divided in two doses, every 12 hours Month 1-3: 10-20 ng/mL Month \u2265 4: 5-15 ng/mL PEDIATRIC Patient Population Initial Oral Dosage Whole Blood Trough Concentration Range Kidney Transplant 0.3 mg/kg/day capsules divided into two doses, every 12 hours. Month 1-12: 5-20 ng/mL Liver Transplant 0.15-0.2 mg/kg/day capsules divided in two doses, every 12 hours Month 1-12: 5-20 ng/mL Heart Transplant 0.3 mg/kg/day 2 capsules divided in two doses, every 12 hours Month 1-12: 5-20 ng/mL 2. Dose at 0.1 mg/kg/day if antibody induction treatment is administered.",
    "adverseReactions_original": "Tacrolimus capsules are contraindicated in patients with a hypersensitivity to tacrolimus. Tacrolimus injection is contraindicated in patients with a hypersensitivity to HCO-60 (polyoxyl 60 hydrogenated castor oil). Hypersensitivity symptoms reported include dyspnea, rash, pruritus, and acute respiratory distress syndrome [see Adverse Reactions (6)].",
    "drug": [
        {
            "name": "Tacrolimus",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00864"
        }
    ]
}